CTRI/2014/11/005188已完成3 期
Comparative Efficacy, Safety and Tolerability of Silver Sulfadiazine Cream (Nanonized) 0.5% w/w and Silverex Cream 1% w/w in the Prophylaxis of Infection in Burn Wounds â?? A Double-Blind, Randomized, Pivotal Study
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects of either sex aged between 12 and 65 years (both inclusive) and who have given written informed consent or assent to participate in the study. Additional written informed consent will be taken from parents or legally acceptable representative (LAR) [as applicable] in case assent is taken from subjects aged less than 18 yrs
- •2. Subjects with partial thickness burns of thermal origin covering 5-10% (both inclusive) of the total body surface area (TBSA) and suitable for outpatient management.
- •3. Subjects in whom burn injury is less than 24 hours old at the time of screening.
- •4. Subjects with clean, non-infected wound as judged by the investigator.
排除标准
- •1. Subjects with history of hypersensitivity to silver sulfadiazine, other sulfonamides, chlorhexidine or any of the excipients of study formulations.
- •2. Subjects with burn wounds associated with chemical, electrical or inhalational injury.
- •3. Subjects with full thickness burns (a burn involving destruction of the entire epidermis and dermis, leaving no residual epidermal cells to repopulate) or circumferential burns (a burn which encircles an entire body part) or superficial burn (a burn which remains confined to the epidermis).
- •4. Subjects with burns involving genitalia, head (including face) or perineum
- •5. Subjects with burns of hands or feet or major joints likely to cause functional impairment.
- •6. Subjects with burns and concomitant trauma (such as fractures) in which the burn injury poses the greatest risk of morbidity and mortality.
- •7. Burn injury in subjects with preexisting medical disorders (e.g., diabetes mellitus, cancer or other immunocompromising conditions) that could complicate management, prolong recovery, or affect mortality.
- •8. Subjects who are under treatment with topical or systemic steroid medications or immunosuppressive agents.
- •9. Subjects with significant disease(s) or disorder(s) other than burn injury that in the opinion of the investigator may (i) put the subject at risk because of participation in the study (ii) interfere with the study evaluations or (iii) cause concern regarding subjectâ??s ability to participate in the study.
- •10. Subjects with history of glucose-6-phosphate dehydrogenase deficiency.
- •11. Subjects with history of substance abuse as per DSM IV criteria.
- •12. Pregnant or breast-feeding women or women of child-bearing potential not using medically acceptable methods of contraception or women with positive urine pregnancy test at screening.
- •13. Subjects who are unable or unwilling to comply with the study procedures.
- •14. Subjects who have participated in another investigational study within the last 1 month prior to entry in this study.
研究者
相似试验
已完成
2 期
Comparative study of Silver sulfadiazine cream (nanonized)and Silverex cream in burns woundsCTRI/2011/09/002030Ranbaxy Laboratories Ltd36
尚未招募
不适用
Comparison of two inject able iron preparations for treatment of iron deficiency anemia in pregnancyCTRI/2019/02/017553Department of Obstetrics and Gynecology
尚未招募
Unknown
Effect of products on pimplesCTRI/2024/08/072208KOP research centre private limited
已完成
3 期
Cefozopran injection in treatment of community acquired pneumoniaCTRI/2013/02/003366Ranbaxy Research Laboratories100
已完成
3 期
Cefozopran injection in treatment of complicated urinary tract infection and pyelonephritisCTRI/2013/02/003340Ranbaxy Laboratories Ltd100